Logo image of ALLK

ALLAKOS INC (ALLK) Stock Fundamental Analysis

NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD

0.27  +0.02 (+7.02%)

Premarket: 0.279 +0.01 (+3.33%)

Fundamental Rating

2

Overall ALLK gets a fundamental rating of 2 out of 10. We evaluated ALLK against 572 industry peers in the Biotechnology industry. The financial health of ALLK is average, but there are quite some concerns on its profitability. ALLK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALLK had negative earnings in the past year.
ALLK had a negative operating cash flow in the past year.
In the past 5 years ALLK always reported negative net income.
ALLK had a negative operating cash flow in each of the past 5 years.
ALLK Yearly Net Income VS EBIT VS OCF VS FCFALLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

ALLK's Return On Assets of -143.65% is on the low side compared to the rest of the industry. ALLK is outperformed by 83.89% of its industry peers.
Looking at the Return On Equity, with a value of -245.72%, ALLK is doing worse than 71.33% of the companies in the same industry.
Industry RankSector Rank
ROA -143.65%
ROE -245.72%
ROIC N/A
ROA(3y)-69.83%
ROA(5y)-49.47%
ROE(3y)-91.22%
ROE(5y)-62.87%
ROIC(3y)N/A
ROIC(5y)N/A
ALLK Yearly ROA, ROE, ROICALLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

ALLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLK Yearly Profit, Operating, Gross MarginsALLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALLK has more shares outstanding
The number of shares outstanding for ALLK has been increased compared to 5 years ago.
There is no outstanding debt for ALLK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALLK Yearly Shares OutstandingALLK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ALLK Yearly Total Debt VS Total AssetsALLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

ALLK has an Altman-Z score of -17.05. This is a bad value and indicates that ALLK is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.05, ALLK is doing worse than 84.78% of the companies in the same industry.
ALLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.05
ROIC/WACCN/A
WACCN/A
ALLK Yearly LT Debt VS Equity VS FCFALLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.08 indicates that ALLK has no problem at all paying its short term obligations.
ALLK has a better Current ratio (6.08) than 61.59% of its industry peers.
ALLK has a Quick Ratio of 6.08. This indicates that ALLK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALLK (6.08) is better than 62.12% of its industry peers.
Industry RankSector Rank
Current Ratio 6.08
Quick Ratio 6.08
ALLK Yearly Current Assets VS Current LiabilitesALLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

ALLK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.73%.
EPS 1Y (TTM)-5.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALLK will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.01% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.46%
EPS Next 2Y30.55%
EPS Next 3Y21.51%
EPS Next 5Y13.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLK Yearly Revenue VS EstimatesALLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
ALLK Yearly EPS VS EstimatesALLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALLK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLK Price Earnings VS Forward Price EarningsALLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLK Per share dataALLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

ALLK's earnings are expected to grow with 21.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.55%
EPS Next 3Y21.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALLK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLAKOS INC

NASDAQ:ALLK (2/5/2025, 8:00:00 PM)

Premarket: 0.279 +0.01 (+3.33%)

0.27

+0.02 (+7.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners88.1%
Inst Owner Change-0.02%
Ins Owners1.47%
Ins Owner Change-5.64%
Market Cap24.12M
Analysts73.85
Price Target1.22 (351.85%)
Short Float %1.05%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)11.48%
Max EPS beat(2)17.22%
EPS beat(4)2
Avg EPS beat(4)-22.01%
Min EPS beat(4)-69.86%
Max EPS beat(4)17.22%
EPS beat(8)5
Avg EPS beat(8)-8.62%
EPS beat(12)6
Avg EPS beat(12)-12.4%
EPS beat(16)8
Avg EPS beat(16)-10.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-64.18%
PT rev (3m)-56.68%
EPS NQ rev (1m)12.44%
EPS NQ rev (3m)13.52%
EPS NY rev (1m)1.38%
EPS NY rev (3m)3.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-2.03
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -143.65%
ROE -245.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.83%
ROA(5y)-49.47%
ROE(3y)-91.22%
ROE(5y)-62.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.08
Quick Ratio 6.08
Altman-Z -17.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)521.85%
Cap/Depr(5y)331.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y28.46%
EPS Next 2Y30.55%
EPS Next 3Y21.51%
EPS Next 5Y13.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.21%
EBIT Next 3Y18.72%
EBIT Next 5Y26.45%
FCF growth 1Y67.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.7%
OCF growth 3YN/A
OCF growth 5YN/A